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Specific mutations in the D1–D2 linker region of VCP/p97
enhance ATPase activity and confer resistance to VCP
inhibitors
Prabhakar Bastola1, Feng Wang2, Matthew A Schaich3,4, Taiping Gan2, Bret D Freudenthal3,4, Tsui-Fen Chou2 and Jeremy Chien1,5
Valosin-containing protein (VCP), together with several partner proteins, extracts ubiquitinated client proteins from E3 ligase
complex and facilitates their degradation through ubiquitin–proteasome system. Therefore, it plays an important role in regulating
protein quality control and various cellular pathways. Recent studies also identified VCP as a lineage-specific essential gene in
ovarian cancer. An orally bioavailable VCP inhibitor, CB-5083, is currently in Phase I clinical trials because it shows therapeutic
effects in multiple tumor xenograft models. However, the mechanism of resistance to CB-5083 is unknown. Here, we characterized
molecular mechanism of resistance to CB-5083. Using incremental exposure to CB-5083, we established CB-5083-resistant ovarian
cancer cells that showed five- to six-fold resistance in vitro compared with parental cells. Genomic and complementary DNA
sequencing of the VCP coding region revealed a pattern of co-selected mutations: (1) missense mutations at codon 470 in one copy
resulting in increased ATPase activity and (2) nonsense or frameshift mutations at codon 606 or codon 616 in another copy causing
the loss of allele-specific expression. Unbiased molecular docking studies showed codon 470 as a putative binding site for CB-5083.
Furthermore, the analysis of somatic mutations in cancer genomes from the Cancer Genome Atlas (TCGA) indicated that codon 616
contains hotspot mutations in VCP. Thus, identification of these mutations associated with in vitro resistance to VCP inhibitors may
be useful as potential theranostic markers while screening for patients to enroll in clinical trials. VCP has emerged as a viable
therapeutic target for several cancer types, and therefore targeting such hyperactive VCP mutants should aid in improving the
therapeutic outcome in cancer patients.
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INTRODUCTION
Valosin-containing protein (also known as p97 or Cdc48 in yeast)
belongs to AAA (ATPase Associated with diverse cellular Activities)
family of ATPase. The protein has an N terminal domain, two
ATPase domains (D1 and D2), followed by a short C terminal
extension.1–4 These domains are linked via two linker regions
between N and D1 as well as D1 and D2.2 While the N-terminal
domain mostly interacts with substrates and co-factors, both D1
and D2 domains bind and hydrolyze ATP.1,5 Mutations in the D2
domain that prevent binding of ATP or abolish ATP hydrolysis
result in a dominant-negative phenotype, suggesting that D2
domain is responsible for driving most functions associated with
VCP, while the ATPase activity in D1 domain provides a supportive
function.6 Recently solved high-resolution cryoelectron micro-
scopy structure of VCP depicted a two-step ATP-driven conforma-
tional changes associated with VCP activity.2 The structure
revealed that binding of ATP to the D2 domain brings about a
conformational change to D2 and subsequently to D1–D2 linker
region. This allows for ATP binding at D1 domain resulting in the
movement of N-terminal region. The structure uncovers the
significance of the D1–D2 linker region and demonstrates that
D1–D2 inhibitors causes a steric clash, which abolished the
function of VCP.2
VCP has been linked with various cellular processes including
ubiquitin-mediated degradation,7,8 endoplasmic reticulum (ER)-
associated degradation,9,10 chromatin associated degradation,11
protein aggregate processing,12 endosomal trafficking,13
mitochondria-associated degradation14 and autophagy.15
Although VCP has been implicated in a multitude of cellular
processes, its function in the ATP-mediated extraction of unfolded
proteins from the ER for degradation via proteasome has been
extensively studied.16,17 Similarly, the role of VCP-mediated ATP
hydrolysis in the unfolding of ubiquinated client proteins that are
targeted for degradation by the proteasome is also well
established.18 These functions make VCP an essential component
in protein quality control (PQC). PQC has emerged as an essential
factor in tumor development, and components of PQC have been
proven to be valid targets for cancer therapeutics. Recent
genome-wide shRNA screens identified various components of
PQC, such as proteasomal subunits and VCP, as essential genes in
cancer cells.19,20 Therefore, VCP inhibitors may serve as novel
cancer therapeutics that exploit unique vulnerabilities or depen-
dencies of cancer cells.
Several studies reported the development of VCP inhibitors
and showed that these compounds induce ER stress and
apoptosis in cancer cells.21–23 High-throughput screening of
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compound libraries from Maybridge Hitfinder Collection and
NIH Molecular Libraries Small Molecule Repository yielded in
the identification of DBeQ (N2,N4-dibenzylquinazoline-2,4-
diamine) as a selective, reversible, ATP-competitive inhibitor of
VCP.21 Subsequently, a structure–activity relationship study
was performed using DBeQ and N-benzyl-2-(2-flurorophenyl)
quinazoline-4-amine 1 as a starting point. The study resulted in
the identification of ML240 with improved potency towards
inhibition of D2 ATPase activity.24 A derivative of ML240 was
later developed into CB-5083, which displayed better specifi-
city towards VCP and more importantly showed efficacy in
several tumor xenograft models when administered orally.23,25
Such promising results allowed for the start of two Phase I
clinical trials.
Prompted by the potential application of VCP inhibitors in
cancer, several studies have focused on understanding the
mechanism of resistance towards VCP inhibitors. Cells resistant
to CB-5083 have been shown to harbor mutations in VCP, yet
details regarding the mechanism of resistance are unknown.23
Similarly, prolonged treatment with an allosteric VCP inhibitor,
NMS-873, resulted in a heterozygous A530T mutation in VCP.
However, these resistant cell lines did not show any cross-
resistance towards CB-5083 or other VCP inhibitors.26 These results
suggest that target alterations may represent a molecular
mechanism of resistance to VCP inhibitors.
Given that CB-5083 has entered the realm of clinical trials, we
set out to understand the mechanism of resistance towards this
compound. Here, we established and characterized the in vitro
mechanism of resistance to CB-5083. Our study indicates
target alterations as a potential mechanism of resistance to
CB-5083 in vitro, thereby providing a critical potentially theranostic
marker that should be considered in clinical trial settings. Finally,
our studies highlight the relevance for the further development of
novel VCP inhibitors that can overcome resistance to existing VCP
inhibitors.
RESULTS
Development of CB-5083 resistant cell lines
With oral VCP inhibitor CB-5083 in two Phase 1 clinical trials, we
set out to understand the potential mechanism of resistance
towards CB-5083. Since one of Phase 1 clinical trials for CB-5083
focuses on advanced solid tumors, we selected ovarian cancer cell
line OVSAHO for our studies because it represents a solid tumor
subtype with an aggressive phenotype. To understand the
mechanism of resistance towards CB-5083, we established
CB-5083-resistant cell lines as outlined in Figure 1a. We incubated
OVSAHO cells with 2.5 μM of CB-5083 for 24 h, which resulted in
significant cell death (data not shown). Cells were allowed to
recover in the drug-free medium for 5–10 days. Three more
rounds of treatment and recovery were performed with the
incremental increase of 0.5 μM of CB-5083 per round (Figure 1a).
After four rounds of incremental exposure to CB-5083, we
observed a small increase in resistance to CB-5083 in recovered
cells (OVSAHO-R) compared with parental cells (Figure 1b). Next,
we treated 500 OVSAHO-R cells with either 2 μM CB-5083 or 3 μM
CB-5083 continuously for 15 days. Surviving cells were allowed to
form colonies and expanded separately to get two separate
populations of resistant cells (O-CB-R1 and O-CB-R2). Both
surviving resistant cell populations displayed an elongated cell
structure in contrast to rounded cell morphology of parental
OVSAHO cells (Figure 1f and Supplementary Figure S1C). Com-
pared with parental line, O-CB-R1 and O-CB-R2 cells lines showed
5.3- and 5.7-fold increase in resistance towards CB-5083,
respectively (Figures 1d, e and 2c and Supplementary Figures
S1A and B).
Molecular characterization of resistance cell lines
We have previously shown that VCP knockdown cells were more
sensitive to VCP inhibitors than VCP-proficient cells.27 In contrast,
we observed a decrease in both mRNA as well as protein level in
Figure 1. Development of CB-5083-resistant cells. (a) Experimental setup used to generate the initial OVSAHO-resistant cells. (b) Colony
formation assay was performed on parental OVSAHO cells and OVSAHO-R (resistant) cells. Cells were treated with different concentrations of
CB-5083 between 0.5–2.5 μM for 48 h and then allowed to recover under normal media for eight additional days. (c) Experimental setup used
to generate O-CB-R1 and O-CB-R2 from OVSAHO-R. (d) OVSAHO parental, O-CB-R1 and O-CB-R2 were incubated with incremental doses of
CB-5083 (0.1 –10 μM) for 72 h and cell viability was determined using SRB assay. Dose–response curves were generated via GraphPad Prism
using four parameters nonlinear regression and the curves were constrained on top (100%) and bottom (40%). Every point in the dose
response curve represents Mean± S.E.M. taken from at least duplicate samples for all cell lines. (e) The bar graph represents Mean GI50+S.E.M.
taken from three independent experiments in all cell lines. P-values were calculated using Student’s t-test. (f) Images of OVSAHO parental,
O-CB-R1 and O-CB-R2 were taken using a Zeiss light microscope at × 100 magnification. **P valuep0.01.
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both resistant cell lines compared with parental (Figures 2a and b).
Furthermore, we examined the cytotoxicity of several VCP
inhibitors and the proteasome inhibitor bortezomib. Compared
with parental cells, only NMS-873 displayed cross-resistance in
O-CB-R1 and O-CB-R2 (Figure 2c and Supplementary Figure S2).
Surprisingly, we were unable to observe cross-resistance towards
DBeQ and ML240, which share close chemical structure to
CB-5083. We also did not observe cross-resistance to the recently
described allosteric VCP inhibitor UPCDC30425 as well as the
proteasome inhibitor bortezomib (Figure 2c and Supplementary
Figure S2).
CB-5083 treatment has been shown to induce unresolved
unfolded protein response (UPR), resulting in apoptosis.23,27
Therefore, we evaluated UPR signaling with VCP inhibitors
(CB-5083 and DBeQ), a proteasome inhibitor (bortezomib) and
an ER-stress inducer (tunicamycin). Based on our cytotoxicity data,
we expected CB-5083 treatment to have a reduced activation of
UPR signaling in resistance cells. As expected, we observed
reduced activation of ATF4 at both 3 and 6 h time-point in
resistant cells (Figure 2d). We also observed the reduction of ATF4
with DBeQ, bortezomib and tunicamycin treatments (Figure 2d).
Since tunicamycin and bortezomib do not bind to VCP, reduced
ATF4 expression in resistant cell lines suggests that these cells
might have acquired increased adaptive capacity to handle ER
stress.
CB-5083-resistant cells harbor mutations in the D1–D2 linker
region of VCP
Based on previous studies indicating that CB-5083-resistant cells
harbor mutations in VCP,23,25 we decided to sequence specific
regions of VCP gene. CB-5083 has been shown to be a D2 specific
inhibitor;23,25 therefore, we sequenced all the exons spanning the
D2 domain (exons 13–16). Similarly, homozygous point mutations
at the D1–D2 linker region were observed in CB-5083-resistant
cells.23 Hence, we decided to sequence exons 11 and 12 as well. In
O-CB-R2, we identified one heterozygous mutation at codon 470
(E470K, exon 12) and one heterozygous mutation at codon 603
(Q603*, exon 14) (Figure 3a). In another resistant cell line, O-CB-R1,
we found two heterozygous mutations at codon 470 (E470K and
E470D, exon 12), one heterozygous mutation at codon 603
(Q603*, exon 14) and one heterozygous frameshift deletion
(N616Mfs, exon 14) (Figure 3a). Since both O-CB-R1 and O-CB-R2
contained a mixed population of cells and could, therefore, harbor
heterogeneous mutations in VCP, we isolated several single clones
from both the resistant cell populations. We generated three
individual clones from O-CB-R2, and all three clones harbored a
heterozygous E470K mutation in VCP (data not shown).
We also generated two individual clones from O-CB-R1 (O-CB-
R1.1 and O-CB-R1.2), and observed two separate heterozygous
mutations, E470K and E470D, in O-CB-R1.1 and O-CB-R1.2,
respectively (Figure 3a). O-CB-R1.1 cells also contained a hetero-
zygous nonsense mutation at codon 603 (Q603*, exon 14). In
contrast, O-CB-R1.2 cells contained a heterozygous frameshift
deletion at codon 616 (N616Mfs*63, exon 14) (Figure 3a). Similar
to O-CB-R1, both O-CB-R1.1 and O-CB-R1.2 displayed a significant
increase in GI50 compared with parental OVSAHO when treated
with CB-5083 (Supplementary Figure S4A). In addition, analysis of
somatic mutations in VCP in tumor samples from TCGA data set
indicated that frameshift mutations at codon 616 in VCP are
frequently observed in cancer samples (Supplementary Figures
S4B and C). Previous study identified several homozygous point
mutations along the D1–D2 linker region (codons 472, 473 and
474) in CB-5083-resistant cells.23 The clusters of mutations within
this region further highlights the importance of D1–D2 linker in
the mechanism of resistance to VCP inhibitors.
To determine if heterozygous mutations at codons 470 and
603/616 are compound mutations present in both alleles or
mutations present separately in two alleles, we decided to
sequence the cDNA. In contrast to DNA sequencing results, we
detected homozygous mutations at codon 470 while no mutation
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Compound Parental O-CB-R1 O-CB-R2
CB-5083 0.6±0.05 3.19±0.45 (5.3) 3.40±0.55 (5.7)
NMS-873 3.3±0.08 12.2±1.55 (3.7) 11.6±1.86 (3.5)
ML240 2.5±0.6 2.5±0.6 2.5±0.6
DBeQ 7.0±0.8 6.4±0.7 7.1±0.9
UPCDC30245 2.5±0.4 2.6±0.2 2.6±0.5
Bortezomib 0.28±0.08 0.33±0.10 0.33±0.10
Figure 2. Effects on VCP/p97 mRNA and protein expression, cross-resistance and changes in unfolded protein response (UPR) in resistant cell
line. (a) Quantitative RT-PCR was performed to evaluate the mRNA expression of VCP in OVSAHO parental, O-CB-R1 and O-CB-R2. Bar graph
represents the mean relative mRNA expression+S.E.M. normalized to 18 S from three independent experiments. P-values were calculated
using Student’s t-test. (b) Whole-cell lysates were immunoblotted and probed with the antibody against VCP to evaluate the protein
expression. β-Actin was used as the loading control. Numbers indicate relative VCP expression normalized to the β-actin loading control.
(c) Table displays Mean GI50± S.E.M. (μM) with several VCP inhibitors and proteasome inhibitor (Bortezomib) from three independent
experiments in parental and resistant cells. Numbers in the bracket for CB-5083 and NMS-873 treatment represent the drug resistance index
(DRI) in resistant cells compared with parental cells. (d) OVSAHO parental, O-CB-R1 and O-CB-R2 were treated with CB-5083, DBeQ, bortezomib
or tunicamycin at indicated concentrations. Cells were collected at 3 and 6 h time-points and whole-cell lysates were subjected to
immunoblotting and probed with indicated antibodies. Numbers indicate relative ATF4 protein expression normalized to β-actin (loading
control). **P valuep0.01.
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was detected at codon 603 or 616 in the cDNA (Figure 3b). These
results suggest that mutations at codons 470 and 603/616 are not
compound mutations present in the same allele. In fact, these
results suggest the first set of mutations at codon 470 (E470K or
E470D) are present in one VCP allele while another set of
mutations at codons 603 (Q603*) or 616 (N616Mfs*63) are present
in the other VCP allele. Although VCP mRNA with E470K or E470D
mutations is expressed and can be detected in cDNA sequencing
as homozygous mutations, the VCP mRNA with either Q603* or
N616Mfs* 63 mutations is not expressed because of nonsense-
mediated decay, and therefore they are not detected in the cDNA
sequencing.
E470K and E470D mutants show higher ATPase activity and
increased resistance than wild-type VCP
To determine the effect of specific missense mutations on VCP
ATPase activity, we performed site-directed mutagenesis of a
bacterial expression construct containing VCP as previously
described.28 The list of plasmids used to purify VCP/p97 proteins
is shown in Supplementary Figure S5C. Wild type and two mutant
form of VCP proteins were purified according to our published
procedure,28 and Biomol Green reagent (a modified Malachite
Green assay) was used to determine ATPase activity. Figure 4a
demonstrated that E470D and E470K have elevated ATPase
activity, about 5.8- and 3.4-fold, respectively. Next, we determined
in vitro IC50 of CB-5083, NMS-873, ML240, ML241 and DBeQ
(Figures 4b–d and Supplementary Figures S5A and B). Our result
indicated that CB-5083 was about 3.4- to 3.8-fold less active in
inhibiting E470 mutants than WT VCP and interestingly, ML240
was about 15-fold less active (Figures 4b and d). The allosteric
inhibitor NMS-873 was about 2.6–2.9-fold less active toward E470
mutant (Figure 4c). Increased IC50 in E470 mutants was also
observed with ML241 and DBeQ (Supplementary Figures S5A and
B). These results show E470 mutants have increased ATPase
activity and resistance to a broad spectrum of VCP inhibitors.
Mutation at E470 may affect binding to CB-5083 and NMS-873
To determine the binding site of CB-5083, and therefore possible
impacts of E470 mutations, we utilized the molecular docking
program AutoDock Vina with a 2.4 Å hexameric structure of VCP
(PDB code 5FTK) (Figure 5a).2,29 A search for binding sites of
CB-5083 was performed on a hexameric VCP with a 30× 30× 30 Å3
cubic region oriented near the mutation site while keeping the D2
active site of the enzyme within the search box. Two thermo-
dynamically similar binding modes were observed: one was at the
D1–D2 interface with the methyl group from the benzimidazole
ring in contact with E470. The carbon molecule of the attached
methyl group is 4.3 Å from both the carbon two and three of E470
Figure 3. CB-5083-resistant cell lines harbor heterozygous mutations at exon 12 and exon 14. (a) Chromatograms displaying the region of VCP
genomic DNA coding sequence at exon 12 and exon 14 in OVSAHO parental, O-CB-R2 and O-CB-R1 as well as two pure sub-clones O-CB-R1.1
and O-CB-R1.2 generated from O-CB-R1. Blue box marks codons 470, 603 and 616 that harbors mutations in the resistant clones.
(b) Chromatograms displaying the region of VCP c-DNA in OVSAHO parental, OVSAHO-CB-R2, OVSAHO-CB-R1.1 and OVSAHO-CB-R1.2. Blue
box marks codon 470, 603 and 616.
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(Figures 5b and c). The calculated free energy for ligand binding of
that mode was − 8.9 kcal/mol. A previous docking study observed
binding of CB-5083 at the ATP binding site of D2.25 However, the
search parameters used were centered on the D2 active site of
VCP and did not include the D1–D2 interface region.25
Similar to the previous study, we also observed an additional
binding pocket in the active site of the D2 domain with similar
thermodynamic favorability of binding (−9.5 kcal/mol), suggesting
CB-5083 can bind at both the D1–D2 linker and the ATP binding
site, which may account for its previous characterization as a
Figure 4. Mutations at codon 470 enhance VCP activity and attenuate VCP inhibitors function. (a) Time-dependent experiment with wild-type
(WT) VCP/p97 and two E470 mutants to determine their specific ATPase activities. Specific ATPase activity of VCP proteins presented in the
figure was measured in nmol/min/nmol. (b–d) Titration curves of CB-5083, NMS-873 and ML240 for WT, E470K and E470D VCP proteins. IC50
(μM) was calculated using GraphPad Prism with the equation [log(agonist) versus response−Variable slope (four parameters)].
Figure 5. Molecular docking of CB-5083 and NMS-873 into VCP. (a) A structural overview of two subunits of the VCP hexamer, with one in
shades of blue and one in shades of green. The lightest shade represents the N terminal domain, the medium shade represents the D1 ATPase
domain and the darkest shade represents the D2 ATPase domain, as labeled. The mutation site E470 is labeled and in red. The binding sites
near the D1–D2 linker of CB-5083 and NMS-873 are labeled. (b) The primary binding mode of CB-5083, in the interface between the D1 and D2
subdomains. (c) A close-up view of the binding site of CB-5083, with distances to E470 marked. (d) The primary binding mode of NMS-873, at
the interface of two VCP subunits and the D1–D2 linker, which is also in close proximity to the mutation site E470. (e) A close-up view of the
primary binding mode of NMS-873, with distances to the mutation site marked in Angstrom.
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competitive inhibitor. However, based on our cellular studies the
likely mode of action within our experimental design is through
interfacial binding near E470, and mutations at E470 would likely
alter binding of CB-5083. We also performed docking studies on
NMS-873 because our resistant cell lines O-CB-R1 and O-CB-R2
displayed cross-resistance (Figure 2c). NMS-873 has been pre-
viously shown to be an allosteric inhibitor of VCP and binds at the
interface between the D1 and D2 domains.30 Molecular docking of
this compound into hexameric VCP with the same search
parameters outlined for CB-5083 yielded binding modes at the
interface (−9.9 kcal/mol) with direct contacts to E470 (Figures 5d
and e). This is consistent with mutations at E470 promoting
resistance due to disruption of NMS-873 binding.
DISCUSSION
We observed acquired mutations in VCP in ovarian cancer cells
upon the acquisition of in vitro resistance to CB-5083. In particular,
we consistently observed mutations at E470 in the resistant
clones. Our results also indicate that specific substitutions, such as
E470K or E470D, enhance the in vitro ATPase activity. Consistent
with enhanced ATPase activities of these mutants, higher
concentrations of CB-5083 were required to inhibit the activities
of these mutants. Although these studies highlight the specificity
of VCP inhibition by CB-5083 and the cytotoxic effect produced by
VCP inhibition, our studies also provide an important cautionary
note in the development of novel therapeutics targeting VCP.
Cancer cells can rapidly acquire activating mutations in VCP that
could bypass the effect of CB-5083.
Codon 470 is located in the linker region between D1 and D2
domains of VCP. Utilizing Cryo-EM, previous studies solved the
structure of VCP bound to another inhibitor UPCDC30245, and the
results indicate that UPCDC30245 binds to the linker region
between D1 and D2 domains.2 This interaction interferes with the
two-step sequential activation of D2 and D1 by ATP binding.
Docking of CB-5083 to the structure, reported by Banerjee et al.,
suggests that CB-5083 may also associate with the D1–D2 linker
region as well as the active site. Therefore, we speculate that the
mechanism of inhibition of VCP by CB-5083 may be similar to
UPCDC30245, in which binding of a ligand to the interface of the
two domains prevents the ratcheting motion, between D1 and D2
domains, that is required for the function of a full hexamer.2
Future structural studies investigating the interaction between
VCP and CB-5083 are needed to confirm this assertion.
Docking studies suggest that, in addition to binding at the
active site of VCP, CB-5083 may bind to the linker region between
D1 and D2 and interact with residue 470. E470K substitution
could, therefore, disrupt the hydrophobic interaction between
CB-5083 and E470 and interfere with that binding mode. Although
the full effect of the mutation cannot be completely understood
by docking alone, it is possible that amino acid substitution
partially occludes the CB-5083 binding site, making CB-5083
binding less thermodynamically favorable. Therefore, we spec-
ulate that E470 substitutions reduce the affinity to CB-5083 and
promote resistance to CB-5083.
In addition to the potential direct effect of E470 mutations on
the ligand and target interactions, two other indirect mechanisms
of inhibition could also be speculated. First, mutations at E470
induce confirmation changes that lower binding affinity to VCP
inhibitors. Second, mutations at E470 increase the enzymatic
activity of VCP, and therefore a higher amount of inhibitors is
needed to inhibit VCP mutants. Results from enzymatic in vitro
ATPase assays indicate VCP mutants are more active than the wild-
type VCP. Therefore, activating mutations may contribute to
resistance to VCP inhibitors (Figure 6). These results are similar to
the resistance mechanism associated with kinase inhibitors where
target proteins or other components of the targeted pathway
became mutated to create a bypass mechanism that produces
resistance to kinase inhibitors.31
Figure 6. Graphical abstract elucidating the in vitro mechanism of resistance to CB-5083. Incremental and prolonged exposure to CB-5083
produced cells that acquired resistance to CB-5058. These cells harbor activating missense mutations at codon 470 (E470K or E470D) of VCP
gene in one allele and inactivating nonsense (Q603*) or frameshift stop (N616Mfs*63) mutations in another allele. Although heterozygous
mutations in DNA are detected at these sites, only homozygous mutations at codon 470 are detected in cDNA, suggesting that inactivating
mutations are subjected to nonsense-mediated decay (NMD). The E470 mutants (E470K/E470D) display enhanced ATPase activity and require
higher concentrations of VCP inhibitors to achieve the inhibitory effect.
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It is interesting to note that although E470K and E470D VCP
mutants are resistant to ML240, as indicated by in vitro ATPase
assays, cells with VCP mutants are still sensitive to ML240. One
possible interpretation of the results is that cytotoxicity effect
produced by ML240 is not solely dependent on VCP inhibition.
These results suggest that additional targets of ML240 contribute
to cytotoxicity. It will be important to identify these additional
targets so that ML240 can be further developed as cancer
therapeutics to overcome resistance to CB-5083.
We also observed that CB-5083-resistant cells harbor two
different mutations on separate alleles: (1) an activating mutations
at E470 and (2) an inactivating nonsense mutation at Q603* or a
frameshift deletion at N616. Complementary DNA sequence
analysis of expressed VCP transcripts identified the E470 mutant
transcripts as the primary transcripts. Transcripts containing Q603*
and N616Mfs*63 are undetectable in the cDNA sequence analysis
although these mutations are observed in the DNA sequence
analysis. These results support our conclusion that nonsense
mutations (Q603* and N616Mfs*63) are located in the other VCP
allele and that transcripts produced from this mutant VCP are
subjected to nonsense-mediated decay. Additionally, cells with
mutant VCP show reduced expression of VCP, further providing a
corroborating evidence that one allele is not expressed. Collec-
tively, these results suggest a co-selection of activating and
inactivating mutations in VCP under in vitro CB-5083 selection
pressure.
Finally, we observed inactivating mutations in VCP in tumor
samples reported by the Cancer Genome Atlas (TCGA) sequencing
studies. In particular, truncating mutations at codon 616 are the
most frequent hotspot mutations in VCP in TCGA database. Given
that our in vitro selection with CB-5083 resulted in co-selection of
activating and inactivating mutations in separate VCP alleles, the
pre-existence of truncating mutations at codon 616 may portend
acquired resistance to CB-5083. Therefore, ongoing clinical trials
investigating the therapeutic effect of CB-5083 in cancer should
investigate the theranostic potential of these mutations in cancer
patients enrolled in the clinical trials.
MATERIALS AND METHODS
Cell lines and cell culture
Parental and resistant cells from OVSAHO cell were cultured in RPMI 1640
(Caisson Labs, Smithfield, UT, USA, RPL03) with 10% fetal bovine serum
(Sigma-Aldrich, St. Louis, MO, USA, F0926) with 1% penicillin–streptomycin
solution (Caisson Labs, PSL01) using standard sterile cell culture protocol.
Cells were incubated in a humidified incubator with 5% CO2 at 37 °C. All
cell lines were periodically checked for mycoplasma contamination. The
identity of the cell lines was verified by STR genotyping (Supplementary
Document).
Reagents and chemicals
CB-5083 (Selleckchem, Houston, TX, USA, S8101), ML240 (Sigma-Aldrich,
SML1071), DBeQ (Sigma-Aldrich, SML0031), NMS-873 (Selleckchem, S7285)
and UPCDC30245 (Sigma-Aldrich, SML1674) were dissolved in DMSO to
make a 50 mM stock solution. Tunicamycin (Sigma-Aldrich, T7765) was
dissolved in DMSO to make 10 mM stock solution. The stock solution was
aliquoted and stored at − 80 °C, which was further diluted before making
the final concentrations of the compound in culture media.
Sulforhodamaine B assay
Cell viability following drug treatment was accessed using Sulforhodamine
B (SRB) assay and performed as previously described32 with certain
modifications. 10 000 cells/well were seeded in a 96-well plate and were
allowed to incubate overnight in the humidified incubator. The following
day, media was aspirated from each well and cells were incubated with
fresh media containing different concentrations of the specified com-
pound and further incubated at 37 °C incubator for 72 h.
After drug treatment, the medium was aspirated and cells were fixed
with 10% trichloroacetic acid solution (Sigma-Aldrich, T6399) at 4 °C
overnight. Plates were further processed as previously described.27 Dose–
response curves were generated using GraphPad Prism 6 (La Jolla, CA,
USA). Before obtaining GI50 values, curves were constrained at 100% on
top and greater than 0% on bottom.
Colony formation assay
Colony formation assay was performed as previously described27 with
certain modifications. Briefly, 500 cells were plated in a six-well plate and
incubated overnight at 37 °C in an incubator. Next day, cells were treated
with different concentrations of CB-5083 and incubated for 48 h. The drug-
containing media was aspirated, washed with PBS and replaced with
regular media. Cells were then placed back in the incubator and allowed to
form colonies for 6–8 days additional days replacing media every 2 days.
After the establishment of colonies, media was aspirated and cells were
washed with PBS and stained with SRB dye for 30 min. Excess dye was
removed and the wells were washed with 1% acetic acid. Plates were
allowed to air-dry at room temperature and each plate was photographed
to display the colonies using the Bio-Rad Imager System (Hercules, CA,
USA).
Western blot
0.5 × 106 cells/well were plated in a six-well plate and incubated overnight
using standard cell culture practice. Next day, media was aspirated and
cells were washed twice with PBS. Cells were then incubated with media
containing the compound of interest or the vehicle for the mentioned
time. At the end of treatment, cells were collected using a cell scraper. To
collect the cell pellet, the mixtures were centrifuged at 1000 × g for 5 min
at room temperature and subsequently washed with PBS.
Whole-cell lysates were prepared and western blot analyses were
performed according to the previously established protocol.27 Original
western blot images are provided in Supplementary Figure S6. A complete
list of primary antibodies and dilutions is provided in Supplementary
Figure S3B.
Genomic DNA extraction and Sanger sequencing
1× 106 cells were collected from parental and resistant cell lines. Genomic
DNA was extracted from each sample using Qiagen DNA purification kit
(Qiagen, Hilden, Germany, 69506). Following the genomic DNA purifica-
tion, segments of the VCP gene (exons 11–16) were amplified by PCR with
specific primers. A complete list of all primers can be found in
Supplementary Figure S3A. Following PCR amplification, amplicon length
was evaluated using DNA gel electrophoresis. All samples were PCR purified
(Qiagen, 28104) and sequenced by Sanger sequencing according to GeneWiz
(South Plainfield, NJ, USA) PCR purified protocol. All Sanger sequencing
results were then evaluated using Sequencher (ver 5.0, Gene Codes).
RNA extraction, quantitative RT-PCR and cDNA sequencing
1× 106 cells pellets from each experimental conditions were harvested by
centrifugation after washing with PBS. RNA extraction was performed
using trizol reagent (Invitrogen, Carlsbad, CA, USA, 15596-028) according
to the manufacturer’s protocol. One microgram of total RNA was reverse
transcribed using a random primer (5 μg) and MMLV reverse transcriptase
(Invitrogen) according to the manufacturer’s protocol.
For quantitative RT-PCR, 0.5% of the cDNA reaction mixture was mixed
with Qiagen qPCR SYBR Green Fluor Mastermix (Qiagen, 330513) based on
the manufacturer’s protocol. The list of primers used for qRT-PCR can be
found in Supplementary Figure S3D.
cDNA sequence spanning exon 7 -3′ UTR of VCP was amplified using the
specific primer pairs (Supplementary Figure S3C) and the resulting
amplicon was PCR purified with PCR Purification kit (Qiagen, 28104).
Purified amplicons were sequenced by Sanger sequencing according to
the GeneWiz PCR purified protocol. The results were then evaluated using
Sequencher (ver 5.0, Gene Codes).
Determining IC50 values of p97 inhibitors in ATPase assays
The detailed method was described previously.28 Inhibition of human p97
(25 nM monomer) was carried out in assay buffer (50 mM Tris pH 7.4, 20 mM
MgCl2, 1 mM EDTA, 0.5 mM TCEP) containing 0.01% Triton X-100 and 200 μM
ATP. Eight-dose titration was used to determine IC50 of each compound in
blocking ATPase activity, which was determined through the addition of
Biomol Green Reagent (Enzo Life Sciences, Farmingdale, NY, USA).
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Molecular docking
All molecular docking experiments were carried out with AutoDock
Vina.29 The structure of VCP was acquired from the protein data bank (PDB
code 5FTK), and modified by removing the bound ADP and solvent
molecules, and converted to a hexameric form for CB-5083 and NMS-873.2
Auto-DockTools 4.2 was utilized to add polar hydrogens and Gasteiger
charges and to position a 30 × 30 × 30 Å3 search box that included both
E470 and the active site.33 Structure coordinates of compounds of interest
were built using Phenix and then converted to a.pdbqt format with Auto-
DockTools 4.2, allowing full ligand flexibility.34 Default Autodock Vina
settings were utilized for the analysis of binding modes, except that
exhaustiveness was raised to 100. Measurements and figures were made in
PyMol.35
Analysis of somatic mutations in tumor samples from the Cancer
Genome Atlas (TCGA) database
The database was assessed through the cbioportal website.36 All TCGA
tumor sequencing studies (53 published and unpublished studies) were
selected. The search for VCP genes indicates a total of 139 mutations (111
misense and 28 truncating mutations) in 79 samples. Thirteen samples
have two mutations per sample, and the majority of these mutations have
differences in variant allele frequencies, suggestive of independent or
separate mutations.
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